New Indication Approval Case Study: Victoza of Novo Nordisk A/S
Posted on29 Aug 2017
TagsEli Lilly launched Trulicity, GLP1-agnostics, new indication approval, Novo nordisk, Trulicity, Victoza
Comments0
Novo Nordisk A/S got approval of a new, heart-focused indication for its Victoza – diabetes medicine. This will help Novo Nordisk to... Read More
Insight on XOMA Corp and Novartis Licensing Deal
Novartis has bought the rights to Xoma’s gevokizumab. Novartis AG bagged global commercial license for Xoma Corp.’s anti-IL-1 beta monoclonal antibody gevokizumab... Read More
Otsuka Pharmaceutical and Mylan N.V licensing deal : Otsuka grants license to Mylan to market MDR-TB drug Deltyba in India South Africa
Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan... Read More
STADA Pharma, BioQ Pharma licensing agreement to commercialize 3 ready-to-use infusion products
Specialty pharmaceutical companies, STADA Pharmaceuticals Australia Pty Ltd and BioQ Pharma Incorporated, announced a strategic agreement to commercialize three ready-to-use infusion pharmaceuticals... Read More
The European Commission (EC) granted a marketing authorization of IMRALDI®, an adalimumab biosimilar
Posted on26 Aug 2017
TagsAdalimumab, Anti TNF therapy, BENEPALI, Biogen, Biosimilar, FLIXABI, humira, IMRALDI, Samsung Bioepis
Comments0
The European Commission (EC) granted a marketing authorization for IMRALDI® (also known as SB5), an adalimumab biosimilar referencing Humira®. IMRALDI has been... Read More
Samsung Bioepis and Takeda’s Co-development deal for novel biologics
Korean biosimilars manufacturer Samsung Bioepis Co Ltd. will team up with Japanese drugmaker Takeda Pharmaceutical Company to jointly develop new biologic therapies.... Read More
Case Study: Dr. Reddy’s Out-Licensing deal Of DFD-06 To Encore Dermatology
Dr. Reddy’s Laboratories Ltd., through its wholly owned subsidiary Promius Pharma, LLC announced that it has out-licensed the future development, manufacturing, and... Read More
Case Study: Cipla Health’s Nicotex Nicotine patches launch in Indian Market
Cipla Health, an arm Cipla with a focus on consumer healthcare products, launched Nicotex Nicotine patches. Nicotex Nicotine patch is a skin/transdermal... Read More
Case Study: Pfizer’s BESPONSA® (inotuzumab ozogamicin) – drug development to U.S. FDA Approval
Brand Name: BESPONSA® Company: Pfizer Molecule: Inotuzumab ozogamicin Approved Indication: Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia... Read More